Cargando…
NK cells specifically TCR-dressed to kill cancer cells
BACKGROUND: Adoptive T-cell transfer of therapeutic TCR holds great promise to specifically kill cancer cells, but relies on modifying the patient's own T cells ex vivo before injection. The manufacturing of T cells in a tailor-made setting is a long and expensive process which could be resolve...
Autores principales: | Mensali, Nadia, Dillard, Pierre, Hebeisen, Michael, Lorenz, Susanne, Theodossiou, Theodossis, Myhre, Marit Renée, Fåne, Anne, Gaudernack, Gustav, Kvalheim, Gunnar, Myklebust, June Helen, Inderberg, Else Marit, Wälchli, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413353/ https://www.ncbi.nlm.nih.gov/pubmed/30665853 http://dx.doi.org/10.1016/j.ebiom.2019.01.031 |
Ejemplares similares
-
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019) -
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019) -
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
por: Mensali, Nadia, et al.
Publicado: (2019) -
A TCR-based Chimeric Antigen Receptor
por: Walseng, Even, et al.
Publicado: (2017) -
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)